tiprankstipranks

Matthew Sherman Insider Profile

4 Followers
Matthew Sherman, EVP & Chief Medical Officer at Acceleron Pharma, holds 20.00K shares in Pulmatrix (Ticker: PULM), holds 77.27K shares in Acceleron Pharma (Ticker: XLRN), holds ― shares in Lumos Pharma (Ticker: LUMO).
tipranks
Matthew Sherman

Matthew Sherman
Acceleron Pharma (XLRN)
EVP & Chief Medical Officer

Ranked #25,348 out of 100,202 Corporate Insiders

Profitable Transactions

63%
5 out of 8 Profitable Transactions

Average Return

+5.50%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$120K
100.00%
0.00%
A breakdown of Matthew Sherman's holdings

Insider Roles

Pulmatrix
(PULM)
Director
Palvella Therapeutics
(PVLA)
Director
Roles that Matthew Sherman holds in companies

Most Profitable Insider Trade

Stock:
Deciphera Pharmaceuticals
(DCPH)
Rating:Informative Sell
Date:Feb 18, 2021 - Feb 18, 2022
Return:+82.30%
The most profitable trade made by Matthew Sherman

Matthew Sherman's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
XLRN
Acceleron Pharma
Apr 04, 2018
Uninformative Sell
176.77K
$13.81M
Pulmatrix
Apr 05, 2018
Director
Uninformative Buy
$120.00K
LUMO
Lumos Pharma
Palvella Therapeutics
Director
DCPH
Deciphera Pharmaceuticals
Jun 11, 2024
Uninformative Buy
$0.00
List of latest transactions for each holding click on a transaction to see Matthew Sherman's performance on stock

Matthew Sherman insider profile FAQ

What is the percentage of profitable transactions made by Matthew Sherman?
The percentage of profitable transactions made by Matthew Sherman is 63%.
    What is the average return per transaction made by Matthew Sherman?
    The average return per transaction made by Matthew Sherman is 5.50%.
      What stocks does Matthew Sherman hold?
      Matthew Sherman holds: XLRN, PULM, LUMO, PVLA, DCPH stocks.
        What was Matthew Sherman’s latest transaction?
        Matthew Sherman latest transaction was an Uninformative Buy of ―.
          What was Matthew Sherman's most profitable transaction?
          Matthew Sherman’s most profitable transaction was an Informative Sell of DCPH stock on February 18, 2021. The return on the trade was 82.30%.
            What is Matthew Sherman's role in Acceleron Pharma?
            Matthew Sherman's role in Acceleron Pharma is EVP & Chief Medical Officer.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.